Dipo Olowookere
By Dipo Olowookere
The sale of the Agbara factory of GlaxoSmithKline (GSK) Consumer Nigeria Plc in Ogun State is yet to be concluded, Business Post has learned.
In 2019, the board of the biopharma company said its manufacturing plant in Ogun State would be shut down by the third quarter of 2021 as the firm was restructuring its business model.
According to a statement released on the development, GSK said the production of its drugs and other products would be handled by a “suitable third party local manufacturer,” saying this was the best strategy to “better serve the Nigerian patients and consumers,” as this development will “not impact GSK’s broader commitments to global health in Nigeria and across Africa.”
It explained that, “This restructuring, which would be effective in Q3 2021, involves working with local contract manufacturers for the supply of GSK’s products, where possible.
“This would support the building of local expertise, transfer of technical knowledge and improve local production capacities in the country.”
Business Post gathered that the GSK Agbara factory was to be offloaded in 2022, but it suffered a setback because buyers were sceptical about the outcome of the 2023 general elections and the macroeconomic environment in Nigeria.
This forced the management to offload some parts of the factory in bits, according to the information contained in the audited financial statements of the organisation for 2022.
GSK said at the time it shut down the factory, the plant and machinery, furniture and fittings, and motor vehicles were worth N666 million, N28 million and N21 million, respectively, with plans to have them sold “within a one-year period.”
“However, due to circumstances that arose in the course of the year, which were previously considered unlikely, some of the assets were not sold as at December 31, 2022,” a note from the results stated.
Explaining the reason for this, the company said, “In 2022, the Nigerian economy took a downturn, and the negative perception of the occurrence of the 2023 general elections in Nigeria made businesses stall on making capital investment decisions which affected the sale of these assets.
“The group took necessary action to respond to the change in these circumstances through direct engagement with potential purchasers to complement the bidding approach originally planned.
“Furthermore, the assets have been impaired and are being actively marketed at a price that is reasonable to their fair value, given the change in circumstances.
“During the year, plants and machinery and motor vehicles with carrying amounts of N29.7 million and N4.8 million, respectively, were disposed of during the year through several bidding processes. Net gains of N7.1 million, which arose from the disposals, have been reported in other gains and losses in the statement of profit or loss under the non-operating segment. There are no cumulative income or expenses included in other comprehensive income relating to the assets held for sale.
“Subsequent to 31 December 2022, additional disposals with a carrying amount of N114 million have been made as at the date of approval of these consolidated and separate financial statements. Negotiations and contracting are currently ongoing with several potential buyers for the remaining assets yet to be disposed of, and the directors expect that all assets will be sold in 2023,” it said.
The 2023 general elections were conducted by the Independent National Electoral Commission (INEC), and Mr Bola Tinubu of the ruling All Progressives Congress (APC) was declared the president-elect, though his mandate is being challenged by Mr Peter Obi of the Labour Party and Mr Atiku Abubakar of the Peoples Democratic Party (PDP).
On Thursday, GSK released its financial statements for last year, and the board proposed the payment of a 55 Kobo dividend to shareholders.
This was after the organisation grew its revenue for the year to N25.4 billion from the N22.5 billion achieved in the preceding year, as the profit before tax closed at N1.2 billion as of December 31, 2022, in contrast to N945.8 million as of December 31, 2021, with the post-tax profit closing at N771.2 million compared with the previous year’s N658.8 million.
